Search research articles
Contact Us
Filters
Showing results (111-120 of 119) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 119 results.
The Journal of Clinical Investigation
|
July 1, 2024
Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia
Baskar Ramdas, Neetu Dayal, Ruchi Pandey, et al.
Ejhaem
|
March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemia
Sarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Blood
|
October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Blood Advances
|
October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Jessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
Cancer Chemotherapy and Pharmacology
|
November 10, 2017
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
Ashkan Emadi, Jennie Y Law, Erin T Strovel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, et al.
Thrombosis Research
|
December 18, 2020
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study
Farid Rashidi, Stefano Barco, Farin Kamangar, et al.
Cancer
|
December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia
Rupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Blood
|
September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 119) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 119 results.
The Journal of Clinical Investigation
|
July 1, 2024
Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia
Baskar Ramdas, Neetu Dayal, Ruchi Pandey, et al.
Ejhaem
|
March 11, 2021
Increased body mass index is a risk factor for acute promyelocytic leukemia
Sarah M Kashanian, Andrew Y Li, Moaath Mustafa Ali, et al.
Blood
|
October 18, 2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Amir T Fathi, Hossein Sadrzadeh, Darrell R Borger, et al.
Blood Advances
|
October 30, 2023
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study
Jessica K Altman, Tsila Zuckerman, Jamie Koprivnikar, et al.
Cancer Chemotherapy and Pharmacology
|
November 10, 2017
Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia
Ashkan Emadi, Jennie Y Law, Erin T Strovel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 12, 2022
Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Casey L O'Connell, Maria R Baer, Andreas Due Ørskov, et al.
Thrombosis Research
|
December 18, 2020
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study
Farid Rashidi, Stefano Barco, Farin Kamangar, et al.
Cancer
|
December 21, 2019
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia
Rupa Narayan, Traci M Blonquist, Ashkan Emadi, et al.
Blood
|
September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
Page
of 12